Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:47:54.385Z.
Calculation as of: 2026-10-06T20:47:54.385Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4aebd5d53392a49c55eaf762d12be1f1a7ff494d091d9ceadcd34fda62bcd254
PE RATIO
N/A
Market Cap
$87.27M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.53M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $85.86M | N/A | N/A | N/A | N/A |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | N/A | 3.67 | 3.67 | 3.67 |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 29.66 | 45.53 | 45.53 | 24.63 |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | N/A | N/A | N/A | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $89.44M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.61
Forward EPS (Est.)
$-1.19
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
